Certara is integrating Nvidia’s BioNeMo Agent Toolkit into its AI-driven drug development platform, while Silo Pharma’s subsidiary, QwikAgents, has joined the Nvidia Developer Program to strengthen its AI agent capabilities.
• Nvidia stock is gaining positive traction. Why are NVDA shares climbing?
Certara Integrates Nvidia BioNeMo Into AI Drug Development Platform
Certara said it is partnering with Nvidia to advance its open, integrated AI platform by combining its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.
Under the collaboration, the Nvidia BioNeMo Agent Toolkit will become one of several agentic frameworks available within Certara’s platform.
